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Abstract
Background: Our previous reports demonstrated that abdominal paracentesis drainage (APD) exerts a beneficial
effect on severe acute pancreatitis (SAP) patients. However, the underlying mechanisms for this effectiveness are
not well understood.
Methods: A retrospective cohort of 132 consecutive non-hypertriglyceridemia (HTG)-induced SAP patients with
triglyceride (TG) elevation and pancreatitis-associated ascitic fluid (PAAF) was recruited from May 2010 to May 2015
and included in this study. The patients were divided into two groups: the APD group (n = 68) and the non-APD
group (n = 64). The monitored parameters mainly included mortality, hospital stay, the incidence of further
intervention, levels of serum lipid metabolites and inflammatory factors, parameters related to organ failure and
infections, and severity scores.
Results: The demographic data and severity scores were comparable between the two groups. Compared with the
non-APD group, the primary outcomes (including mortality, hospital stay and the incidence of percutaneous
catheter drainage) in the APD group were improved. The serum levels of lipid metabolites were significantly lower
in the APD group after 2 weeks of treatment than in the non-APD group. Logistic regression analysis indicated that
the decreased extent of free fatty acid (FFA)(odds ratio, 1.435; P = 0.015) was a predictor of clinical improvement
after 2 weeks of treatment.
Conclusion: Treatment with APD benefits non-HTG-induced SAP patients with serum TG elevation by decreasing
serum levels of FFA.
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Background
Our previous research recommended a modified step-up
approach in which a new procedure, abdominal paracen-
tesis drainage (APD), was used during the early stage of
treatment for severe acute pancreatitis (SAP) [1]. We
found that patients with APD had a lower rate of mor-
tality, less organ failure and lower inflammatory factors
than the non-APD group in our retrospective clinical co-
hort study. Furthermore, we investigated the safety of
APD using a prospectively study and confirmed that
there was no increase in the rate of infections with the
APD procedure [2]. These previous studies suggest that
APD could be beneficial in the treatment of patients
with SAP and carries no additional risk of infection [3].
However, the underlying mechanisms for this effective-
ness are not well understood [4].
The possible mechanisms for the effectiveness of APD
could come from two sources: 1) decreasing intra-
abdominal hypertension (IAH); 2) eliminating the toxic
substances, mainly including inflammatory mediators,
proteases and lipid metabolites in pancreatitis-associated
ascitic fluid (PAAF). Among these substances, lipid me-
tabolites, the reaction products of fat necrosis, have been
demonstrated to be involved in the development and
progression of pancreatitis [5–8]. In an experimental
model of SAP, high concentrations of free fatty acid
(FFA) have been detected in PAAF, and the lipid metab-
olites extracted from the PAAF could promote the ex-
acerbation of inflammation in vitro [5]. Recently, FFA in
necrotic collections generated from peri-pancreatic or
visceral fat necrosis have been reported to be a possible
mediator of the conversion of mild acute pancreatitis
(AP) to SAP because of its ability to induce necro-
apoptosis and cause multi-system injury [6].
In addition, triglycerides (TG), which can be trans-
formed into to FFA, have been reported to have a mild-
to-moderate elevated level in plasma (2-10 mmol/L) in
approximately half of the patients with AP [9]. Similar to
FFA, studies have shown that the serum TG elevation
correlates with the aggravation of non-HTG-induced
SAP [10–12]. For example, we recently revealed that
acute biliary pancreatitis (ABP) patients with TG eleva-
tion usually had higher risks of SAP and mortality, more
organ failure and a greater likelihood of requiring fur-
ther intervention compared with those with normal TG
levels. These abovementioned studies indicate that lipid
metabolites, especially TG and FFA, are enriched in
PAAF and play a specific role in the progression of SAP
[12]. Although these advances in knowledge have been
made, the exact roles of lipid metabolites in the effect-
iveness of APD have not been determined.
In this work, we aim to investigate (i) whether APD is
beneficial to non-HTG-induced SAP patients with TG
elevation; (ii) whether removing the PAAF and thereby
removing the lipid metabolites in the fluids could reduce
the level of lipid metabolites in plasma; (iii) whether the
effectiveness of APD correlates with the reduction of
lipid metabolites in plasma. To this aim, we undertook
this retrospective clinical cohort study to assess the clin-
ical effect of APD in non-HTG-induced SAP patients
with elevated serum TG levels and PAAF and investigate




We collected clinical data from consecutive SAP patients
who were admitted to the General Surgery Center from
May 2010 to May 2015. The SAP diagnosis was based
on clinical findings, biochemical parameters, and the
computed tomography severity index (CTSI), according
to the revised Atlanta Classification [13]. The including
criteria were as follows: 1) Adults (older than 18 years)
diagnosed with SAP within 48 h after onset. 2) Fluid collec-
tions in the abdominal or pelvic cavity found via imaging
examinations, such as computed tomography or ultra-
sound. 3) TG level 72 h after onset ≥1.88 mmol/L. 4) No
history of hyperlipidemia or alcohol abuse. The exclusion
criteria were: 1) TG level 72 h after onset ≥11.3 mmol/L. 2)
Primary (genetic) or secondary disorders of lipoprotein
metabolism (e.g., diabetes, obesity, hypothyroidism, drugs
and so on). 3) Patients who had undergone antihyperlipi-
demic therapy, such as insulin and/or heparin treatment,
apheresis and oral drugs during treatment. 4) Patients with
a medical history of immune deficiency, previous abdom-
inal surgery (exploratory laparotomy) or an intraoperative
diagnosis of AP or those who had AP subsequent to an-
other disease. All patients signed written informed consent,
and this study was performed according to the principles
of the Declaration of Helsinki (modified in 2000), and
it was approved by the Ethics Committee of Chengdu
Military General Hospital (No. 2010017).
Group division
The patients were divided into two groups based on
whether they had undergone APD. The patients in the
APD group underwent APD treatment before further
necessary interventions were performed, while the pa-
tients in the non-APD group did not undergo APD dur-
ing treatment.
Management protocols
Non-APD group (routine step-up approach)
Both patient groups initially received conservative treat-
ment, such as rigorous fluid resuscitation and gastrointes-
tinal decompression. Nasojejunal enteral feeding and
antibiotics were used as necessary. In the non-APD group,
when the conservative treatment was not effective and the
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symptoms deteriorated, the treatment advanced to the
second step (percutaneous catheter drainage, PCD) as in-
dicated, similar the procedures described in other reports
[14, 15]. The number, size and location of the catheters
were determined by the size, viscosity and location of the
necrosis, respectively.. The entire procedure was con-
ducted with the cooperation of clinicians and interven-
tional ultrasonographers. If there was no clinical
improvement after the initial PCD, additional catheters
were placed or replaced. Two professional clinicians and
two intervention radiologists assessed the effectiveness of
the PCD procedure. If the PCD treatment yielded no clin-
ical improvement, treatment advanced to the third step –
open surgery – to eliminate the debris and collections.
APD group (modified step-up approach)
A new step, APD, was added for this group after
contrast-enhanced computed tomography (CECT) or
ultrasound detected abdominal or pelvic fluid collec-
tions. The procedure was usually performed within two
weeks after the disease onset. APD involved the place-
ment of a tube to persistently drain the collections from
the abdominal or pelvic cavity. During the treatment
phase, tubes were replaced or added if the initial APD
was not competent. PCD was performed as an additional
step in a manner similar to other reports [14, 15], and
surgery was performed if there was no clinical improve-
ment or if necrosis continued after PCD [15].
Procedures and indications of APD (differences between
APD and PCD)
APD, a new concept that we created, proved in our previ-
ous study to be beneficial to the SAP treatment strategy
because of its supplementary effect when administered
prior to PCD [1]. Although the surgical steps are similar
to those of PCD, there are some differences between the
procedures: First, the APD punctures are performed as
early as possible, usually within two weeks after the onset
of symptoms [1, 2], while PCD is usually performed four
weeks after onset to ensure that there is enough necrosis
to justify the procedure [13, 14]. Second, the APD punc-
ture sites are in the abdominal or pelvic cavity, usually the
right paracolic sulci and left paracolic sulci, while the PCD
sites are in the retroperitoneal space (i.e., the peripancrea-
tic region, left pararenal region, or right pararenal region).
Finally and most importantly, APD and PCD serve differ-
ent purposes: APD is performed to remove fluid collec-
tions in the abdominal or pelvic cavity and thus relieve the
inflammation and organ injury at the early stage of dis-
ease, while PCD mainly targets the elimination of peripan-
creatic necrotic collections in the retroperitoneum to
avoid or treat infected necrotizing pancreatitis (INP). Ac-
cordingly, the indications of the two interventions are dif-
ferent: whenever there is an appropriately high volume of
collections (more than 50-100 ml) and a reachable path-
way can be detected through imaging (usually ultrasound),
APD can performed. In contrast, PCD is performed in pa-
tients who do not demonstrate any improvement or who
deteriorate with routine treatment (as indicated by persist-
ent fever, increased leukocyte counts or an increasing
trend of leukocyte counts, or worsening or new-onset
organ failure, or a diagnosis of INP through CECT or
fine-needle aspiration).
Indications for surgery
At our center, surgery, such as necrosectomy, was per-
formed after PCD for patients with the following indica-
tions: persistent or worsening sepsis after PCD, worsening
or new-onset organ failure, inadequate drainage (<10 ml/
day) of collections and necrosis, and bowel complications
(such as obstruction or uncontrolled fistula) caused by on-
going necrosis [15].
Data collection
First, we collected and analyzed the differences between
the APD group and the non-APD group in terms of
baseline data including age, sex, body mass index (BMI)
and the levels of lipid metabolites (TG, FFA, cholesterol,
lipase) before treatment. Then, we specifically analyzed
the changes in lipid metabolites levels in plasma after
2 weeks of treatment. In addition to mortality, days in
the hospital and detailed information regarding further
interventions were collected as primary clinical out-
comes and were analyzed between the two groups.
Meanwhile, we analyzed other observational parameters
associated with outcomes, such as severity score, infec-
tious factor (white blood cells, procalcitonin, etc.); in-
flammation factors, including tumor necrosis factor-α
(TNF-α), interleukins (ILs), C-reaction protein (CRP);
and organ failure-related parameters at 2 weeks after
treatment.
All laboratory investigations were conducted within
48 h of admission, at 2 weeks after treatment and occa-
sionally thereafter as indicated. CECT was performed
within the first week of the onset of disease, and it was re-
peated at 2 weeks after treatment. Two experienced radi-
ologists calculated and assessed the CTSI scores obtained
from the CECT images. The acute physiology and chronic
health evaluation II (APACHE II) score, Ranson score and
Marshall score were also serially calculated within 48 h
after admission and again at 2 weeks after treatment.
Measurement of FFA determination
Blood samples were collected and centrifuged, and the
serum was stored at -70 °C until analyzed. The total FFA
concentration was measured using the enzymatic method
(Free Fatty Acid Quantitation Kit, Sigma Chemical Co., St.
Louis, MO, USA). The individual FFA measurements were
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conducted as follows: (1) extraction of lipids from the
serum using the Folch and Lees method [16], (2) separ-
ation of lipid fractions using thin-layer chromatography,
(3) methylation of fatty acids, and (4) separation of
fatty acid methyl esters with gas liquid chromatog-
raphy (CP-3800GC, Varian, Japan) using a 30-m capil-
lary column. In this procedure, helium was used as
the carrier gas, and pentadecanoic acid was added as
an internal standard [17].
Statistical analysis
The statistical analysis was performed using SPSS, ver-
sion 17.0 for Windows (SPSS, Inc., Chicago, IL, USA).
The normality of the data was determined using Kolmo-
gorov-Smirnov normality tests. The data were expressed
as the mean ± standard deviation for normally distrib-
uted data and as median and interquartile ranges for
non-normally distributed data. For normally distributed
data, the variables were compared using Student’s t test
for two groups. For skewed data, the Mann-Whitney U
test was used. Qualitative or categorical variables were
described as frequencies and proportions. Proportional
variables were compared using the χ2 test or Fisher’s
exact test. Logistic regression was adopted to assess the
factors that were significant for predicting outcomes after
2 weeks of treatment. All statistical tests were two-tailed
and were performed at a significance level of P < 0.05.
Results
General information and baseline data
A total of 272 non-HTG-induced SAP patients with
fluid collections were admitted to our center between
May 2010 and May 2015; of these, 188 cases (69.12 %)
were accompanied with elevated TG. Among the pa-
tients with elevated TG, 56 were excluded from the
study according to the excluding criteria. Finally, 132 pa-
tients were enrolled in the study, of which 64 received
routine management or sequential PCD and necrosect-
omy if necessary (the non-APD group), and 68 received
APD or sequential APD and PCD intervention before
surgery if necessary (the APD group).
The demographic data of the APD group and the non-
APD group were comparable, as Table 1 shows. In both
groups, the mean levels of TG and other lipid metabo-
lites (total FFA, cholesterol and lipase) were all abnor-
mally elevated, but there were no significant differences
between the two groups. In terms of indicators for body
obesity, the body mass index (BMI), waist-to-hip (WHR)
and waist circumference (WC) of both groups were
higher than normal values, but there were no between-
group differences. Meanwhile, the initial severity scores
of the APD group were similar to those of the non-APD
group. Furthermore, the plasma laboratory parameters
(CRP, IL-1β, IL-6, IL-10 and TNF-α, measured 48 h after
the onset of the inflammation factors) were all abnor-
mally elevated, and there were no differences between
the APD and non-APD groups. Taken together, these re-
sults show that in addition to the abnormal elevation of
inflammation factors, there was also an abnormal eleva-
tion of FFA in the non-HTG-induced SAP patients with
TG elevation.
Primary clinical outcomes in the APD and non-APD
groups
Detail information about the primary clinical outcomes
after treatment for the APD and non-APD groups is
shown in Table 2. The mortality rate in the APD-group
was significantly lower than that of the non-APD group
(5/68, 7.35 % vs 9/64, 14.06 %, P < 0.05). The length of
hospital stay in the APD group was shorter than that of
the non-APD group (52.78 ± 22.51 vs 66.13 ± 33.07, P <
0.05). Before the PCD operation became necessary and
was performed, 23 patients in the APD group (23/68,
33.82 %) demonstrated clinical improvement, which was
significantly more than those who received conservative
treatment only in the non-APD group (12/64, 18.75 %).
In terms of the PCD details, first, the PCD schedule was
significantly altered in the APD group compared with
the non-APD group, and the interval between the onset
of disease and the first PCD insertion was significantly
longer in the APD group compared with the non-APD
group (34.18 ± 5.23 vs 26.73 ± 6.05, P < 0.001). Second,
although the differences were not significant, the PCD
duration was shorter (35.41 ± 7.57 vs 39.37 ± 12.05, P =
0.060) and the total number of PCD procedures per pa-
tient was smaller (4.57 ± 2.35 vs 5.40 ± 2.19, P = 0.075) in
the APD group compared with the non-APD group.
These results suggest that, in non-HTG-induced SAP
patients with elevated serum TG, the APD procedure
could postpone or even avoid further intervention, thus
minimizing the ‘second hit’ that accompanies interven-
tion and consequently reducing both the mortality rate
and the length of hospital stay. Taken together, these re-
sults indicate that treatment with APD benefited the pri-
mary clinical outcomes of the non-HTG-induced SAP
patients with TG elevation.
Organ failure, infection-related parameters, and
inflammatory factors in the APD and non-APD groups
after treatment
The parameters related to organ failure, infections and
inflammation were collected and analyzed after 2 weeks
of treatment (Table 3). Compared with the non-APD
group, in the APD group the duration of organ failure
was shorter (21.29 ± 4.57 vs 23.34 ± 5.33, P = 0.049) and
the recurrence rate of organ failure was lower (11,
30.5 % vs 16, 43.2 %, P < 0.05). Moreover, in terms of the
supporting treatment details, there were fewer instances
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Table 2 The primary clinical outcomes in the APD and non-APD groups
APD group Non-APD group t or χ2 P value
n = 68 n = 64 value
Mortality rate 5/68 (7.35 %) 9/64 (14.06 %) 3.897 0.042*
Hospital stay, days 52.78 ± 22.51 66.13 ± 33.07 4.587 0.037*




Interval between the onset of symptoms
and the first PCD insertion, days
34.18 ± 5.23 26.73 ± 6.05 6.437 <0.001*
Duration of PCD, days 35.41 ± 7.57 39.37 ± 12.05 1.903 0.060
Total NO. Of PCD procedures per patient 4.57 ± 2.35 5.40 ± 2.19 1.799 0.075
Abbreviations: APD abdominal paracentesis drainage, PCD percutaneous catheter drainage
APD-group = patients in this group treated with APD; non-APD group = patients in this group treated without APD. *Significant difference
Table 1 The characteristics of 132 patients enrolled in this study
Characteristic APD group Non-APD group t or χ2 P value
n = 68 n = 64 value
Demographic data (mean ± SD)




BMI(kg/m2) 26.72 ± 1.96 27.19 ± 1.65 1.675 0.096
waist-to-hip (WHR) 1.18 ± 0.08 1.19 ± 0.11 0.600 0.550
waist circumference (WC)(cm) 107.1 ± 12.9 113.5 ± 18.6 0.540 0.479
Lipid metabolites levels of serum
TG (mmol/L) 6.83 ± 2.03 7.12 ± 1.57 0.914 0.362
Total FFA (mmol/L) 1.77 ± 0.22 1.80 ± 0.31 0.644 0.521
Cholesterin (mmol/L) 5.20 ± 0.81 5.07 ± 0.87 0.889 0.376
Lipase (U/L) 1220 ± 277 1195 ± 301 0.497 0.620
Initial severity scores (mean ± SD)
APACHE II score 15.21 ± 3.48(8–65) 15.47 ± 3.10(8–62) 0.452 0.652
CTSI score 8.15 ± 2.87(6–10) 8.22 ± 3.06(6–12) 0.136 0.892
Ranson score 3.27 ± 1.47(1–8) 3.10 ± 1.35(1–8) 0.691 0.491
Marshall score 4.15 ± 1.74(2–6) 4.19 ± 1.23(2–6) 0.152 0.880
Laboratory parameters (mean ± SD)
CRP (mg/L) 143.29 ± 19.73 142.81 ± 20.91 0.136 0.892
IL-1β (pg/L) 14.70 ± 1.21 15.17 ± 2.17 1.232 0.220
IL-6 (pg/L) 351.78 ± 63.21 354.27 ± 50.83 0.248 0.804
IL-10 (pg/L) 149.11 ± 51.39 143.21 ± 50.09 0.667 0.506
TNF-α (pg/L) 19.18 ± 5.33 18.35 ± 4.99 0.922 0.358
Abbreviations: APD abdominal paracentesis drainage, PCD percutaneous catheter drainage
BMI body mass index, WHR waist-to-hip ratio, WC waist circumference, CRP C-reaction protein, IL interleukin, TNF-α tumor necrosis factor-alpha, TG triglycerides,
FFA free fatty acids, APACHE II Acute Physiology and Chronic Health Evaluation II, CTSI computerized tomography severity index, APD group patients in this group
treated with APD, Non-APD group patients in this group treated without APD
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of mechanical ventilation (29 vs 59, P < 0.001) in the
APD group compared with the non-APD group, and
the mean duration of supporting treatment was sig-
nificantly shorter in the APD group (5.27 ± 2.77 vs
7.91 ± 3.05, P < 0.001). These results show that the APD
group had a lower rate of organ failure recurrence and re-
quired less time for the reversal of organ failure.
We estimated the occurrence of infection based on the
incidence of infection, levels of infectious laboratory pa-
rameters and the time required to reverse sepsis. The in-
cidence of infection in the APD group had no significant
change compared with that of the non-APD group (47,
69.11 % vs 46, 71.88 %, P > 0.05). The white blood cell
counts and procalcitonin levels did not vary greatly be-
tween the two groups after treatment. Moreover, for pa-
tients with sepsis, the time required to reverse was
shorter (18.14 ± 2.83 vs 23.76 ± 4.34, P < 0.05) in the
APD group compared with the non-APD group.
Inflammatory factors, such as CRP, IL-1β, IL-10 and TNF-
α were measured to analyze the inflammatory state. In
contrast with the non-APD group, the APD group had sig-
nificantly lower levels of CRP (76.5 ± 22.73 vs 103.5 ± 31.09,
P < 0.001), IL-1β (5.33 ± 1.35 vs 9.97 ± 3.84, P < 0.001), IL-10
(58.7 ± 16.32 vs 65.3 ± 14.16, P = 0.077) and TNF-α (10.1
± 1.07 vs 15.2 ± 2.19, P < 0.001). These results indicated that
the APD group had a more improved inflammatory state
compared with the non-APD group after treatment.
The variation in severity scores after treatment
We employed the APACHE II, Ranson, Marshall and CTSI
scoring systems to determine the severity of disease at
2 weeks after treatment. All scores in both groups were de-
creased after the two types of treatment. However, the
APACHE II scores (8.17 ± 2.13 vs 11.54 ± 3.37, P < 0.001),
Ranson scores (2.55 ± 0.86 vs 2.86 ± 0.92, P = 0.047),
Marshall scores (2.64 ± 0.65 vs 3.91 ± 0.48, P < 0.001) and
CTSI scores (4.88 ± 1.51 vs 5.47 ± 1.83, P = 0.045) were
lower in the APD group compared with the non-APD
group (Fig. 1).
These results indicate that APD could relieve the se-
verity state and reverse the deterioration of progress in
the early stage of SAP, similar to our previous findings.
The change in lipid metabolites after treatment
The concentrations of lipid metabolites, mainly TG and
FFA, decreased after 2 weeks of treatment in both groups
(Table 4). However, the serum levels of TG (2.45 ± 1.07 vs
5.08±2.21, P < 0.001) and total FFA (0.67±0.15 vs 1.33
±0.12, P < 0.001) in the APD group were significantly
lower than those in the non-APD group. Cholesterol and
lipase had slightly lower expression levels in the APD
group compared with the non-APD group, although these
differences were not significant. Furthermore, compared
with the non-APD group, the patients in the APD group
showed more obvious variation in their FFA profiles
(Table 4 and Fig. 1). In terms of the proportional contribu-
tion of individual FFA to the total FFA, compared with the
initial FFA profiles, the percentage of unsaturated fatty
acids (UFA) showed a downward trend with increased
proportions of saturated fatty acids (SFA) in both groups
after treatment (Fig. 2). Remarkably, the proportional con-
tribution of UFA in the APD group decreased significantly
Table 3 Organ failure- and infection-related parameters and inflammatory factors of the APD and non-APD groups
APD group Non-APD group t or χ2 P value
n = 68 n = 64 value
Organ failure
Duration of organ failure, days 21.29 ± 4.57 23.34 ± 5.33 1.993 0.049*
Recurrence rate of organ failure 11 (30.5 %) 16 (43.2 %) 3.410 <0.05*
Mechanical ventilation, N 29 59 36.412 <0.001*
Duration of mechanical ventilation treatment 5.27 ± 2.77 7.91 ± 3.05 3.930 <0.001*
Infection
Incidence of infections 47 46 0.201 0.973
White blood cell count (×109/L) 13.27 ± 3.19 13.25 ± 3.01 0.754 0.518
Procalcitonin > 5 ng/ml 44/68, 64.7 % 39/64, 60.9 % 0.873 0.134
Reversal time of sepsis, days 18.14 ± 2.83 23.76 ± 4.34 2.690 <0.05*
Inflammatory factors
CRP (mg/L) 76.5 ± 22.73 103.5 ± 31.09 34.274 <0.001*
IL-1β (pg/L) 5.33 ± 1.35 9.97 ± 3.84 13.401 <0.001*
IL-10 (pg/L) 58.7 ± 16.32 65.3 ± 14.16 1.782 0.077
TNF-α (pg/L) 10.1 ± 1.07 15.2 ± 2.19 10.954 <0.001*
Abbreviations: APD abdominal paracentesis drainage, PCD percutaneous catheter drainage, CRP C-reaction protein, IL interleukin, TNF-α tumor necrosis factor-alpha,
APD group patients in this group treated with APD, non-APD group patients in this group treated without APD. *Significant difference
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compared with that of the non-APD group (62.67 % vs
39.66 %, P < 0.05).
To further investigate the correlation between APD
and the variation in lipid metabolites levels in plasma,
we analyzed the lipid levels of the PAAF collected during
the initial APD intervention in the APD group. Com-
pared with normal serum concentrations, high levels of
TG and total FFA (TG: 5.17 ± 1.88, FFA: 1.23 ± 0.47)
were observed in the drained PAAF. The concentrations
of lipid metabolites were not as high as those in plasma;
however, this may be due to the consequent dilution of
fluids into the abdominal cavity. Taken together, these
results suggest that the APD procedure could signifi-
cantly decrease the levels of TG and FFA in plasma, and
these variations in plasma might have a correlation with
the drainage of PAAF.
The decreased extents of TG and total FFA were
protective factors
Next, we used univariable and multivariable logistic re-
gression analyses to identify predictors of clinical im-
provement at 2 weeks after treatment. According to the
PANTER trial, "Clinical improvement" is defined as (1)
improved function of organ failure or no new-onset
organ failure, (2) improvement of two out of the follow-
ing three parameters: leucocytes/temperature/CRP.
Table 5 shows the factors indicative of clinical improve-
ment after 2 weeks of treatment. The decreased extents (Δ)
of TG, Δ-FFA and Δ-TNF-a were significantly different be-
tween patients with and without clinical improvement.
Fig. 1 Variation of the severity scores before and after treatment. The severity scores were decreased in both groups after two types of
conservative treatment; moreover, the severity scores of the APD group were lower than that those of the non-APD group
Table 4 The serum levels of metabolites in the APD and
non-APD groups after treatments
APD group Non-APD group t value P value
n = 68 n = 64
Lipid metabolites
TG (mmol/L) 2.45 ± 1.07 5.08 ± 2.21 15.401 <0.001*
Total FFA (mmol/L) 0.67 ± 0.15 1.33 ± 0.12 10.954 <0.001*
Cholesterin (mmol/L) 2.88 ± 0.74 3.01 ± 0.68 1.049 0.296
Lipase (U/L) 195 ± 47 211 ± 56 1.782 0.077
FFA profiles (%)
Lauric acid 12:0 0.92 ± 0.33 0.71 ± 0.23 1.655 0.100
Myristic acid 14:0 6.11 ± 1.81 3.05 ± 0.62 7.598 <0.001*
Palmitic acid 16:0 32.19 ± 9.63 22.61 ± 5.81 9.693 <0.001*
Palmitoleic acid 16:1 4.71 ± 1.57 4.27 ± 2.07 0.157 0.876
Stearic acid 18:0 18.03 ± 5.31 12.50 ± 2.46 10.467 <0.001*
Oleic acid 18:1 25.87 ± 4.73 34.52 ± 6.17 12.363 <0.001*
Linoleic acid 18:2 8.08 ± 0.52 13.31 ± 1.73 23.817 <0.001*
Linolenic acid 18:3 0.33 ± 0.12 0.37 ± 0.18 1.510 0.133
Arachidonic acid 20:4 1.21 ± 0.25 5.41 ± 1.09 6.041 <0.001*
Abbreviations: TG triglycerides, FFA free fatty acids, APD abdominal
paracentesis drainage, PCD percutaneous catheter drainage, APD group
patients in this group treated with APD, non-APD group patients in this group
treated without APD. *Significant difference
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These factors were described as potential predictors of im-
provement after treatment and were analyzed as variables
in the multivariable logistic regression model. In the multi-
variable logistic regression analysis, △-FFA was significantly
different between patients with and without clinical
improvement and thus was identified as protective
factor (Table 6).
For further assessment of the protective effect, the area
under the receiver operating characteristic curve (ROC) of
Δ-FFA was calculated (Fig. 3). It was found that a Δ-FFA of
more than 0.835 mmol/L after 2 weeks of treatment could
predict clinical improvement with a sensitivity of 71.0 %
and a specificity of 86.6 %. Notably, the value of Δ-FFA in
the APD group was 1.07 ± 0.21 mmol/L, which was higher
than 0.835 mmol/L. In contrast, the value of Δ-FFA in the
non-APD group was only 0.48 ± 0.10 mmol/L. These data
indicated the clinical improvement of APD on SAP patients
correlated to the decreased extents of total FFA.
Discussion
In this study, a novel mechanism was proposed that in-
dicates the APD exerts beneficial effects on SAP patients
by reducing the serum levels of TG and FFA. The im-
portant findings are that (i) APD is beneficial for non-
HTG-induced SAP patients with TG elevation; (ii) APD
could reduce the level of serum TG and FFA; and (iii)
The effectiveness of APD has a clear correlation with
the reduction of FFA in plasma. These findings provide
new insight into the indications for APD and the mecha-
nisms for its effectiveness, which may advance the clin-
ical efficacy of APD for SAP.
APD could benefit SAP patients with TG elevation
In recent years, many studies have shown that SAP pa-
tients with elevated plasma levels of TG or FFA usually
exhibit a trend toward aggravation and have a worse
outcome compared with those with normal TG or FFA
levels [6, 10–12, 18]. Therefore, effective strategies for
treating this subset of patients need to be developed. In
our current study, we first determined the clinical effi-
cacy of APD in non-HTG-induced SAP patients with
TG elevation and PAAF. Compared with the non-APD
group, the APD group showed lower mortality and a
shorter mean duration of hospital stay, which suggests
that APD could improve the primary outcomes of this
subset of SAP patients. Moreover, the APD group
showed a lower mean duration of organ failure and sup-
porting treatment and a lower rate of organ failure re-
currence compared with the non-APD group, which
suggests that APD has a reversal effect on organ failure.
The serum levels of inflammatory factors were also
Fig. 2 The variation in FFA profiles before and after treatment in both groups. The percentage of UFA decreased in both groups, and the extent
of the decrease was greater in the APD group than in the non-APD group (62.67 % vs 39.66 %, P < 0.001)
Table 5 Univariable logistic regression analysis of clinical
improvement after treatment
Variable 95 % CI OR
OR Lower Upper P value
Δ-TG 1.672 1.496 2.842 0.017*
Δ-Total FFA 1.650 1.524 1.737 0.034*
Δ-CRP 2.152 2.353 3.891 0.109
Δ-IL-1β 1.796 0.660 1.960 0.017
Δ-TNF-α 1.939 1.887 2.994 0.031*
Abbreviations: TG triglycerides, FFA free fatty acids, CRP C-reaction protein, IL
interleukin, TNF-α tumor necrosis factor-alpha, Δ the extent of decreased level
after 2 weeks of treatment. *Significant difference
Table 6 Multivariable logistic regression analysis of clinical
improvement after treatment
95 % CI OR
Variable OR Lower Upper P value
Δ-TG 3.672 2.196 6.142 0.070
Δ-Total FFA 1.435 1.124 3.234 0.015*
Δ-TNF-α 1.939 0.887 2.994 0.131
Abbreviations: TG triglycerides, FFA free fatty acids, TNF-α tumor
necrosis factor-alpha
Δ = the extent of decreased level after 2 weeks of treatment.
*Significant difference
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significantly decreased in the APD group compared with
the non-APD group, which indicates that APD could re-
lieve systemic inflammation. In addition, the APD group
showed more improved severity scores after treatment
compared with the non-APD group. Furthermore, the need
for additional intervention (PCD) was postponed, and the
incidence of PCD was lower in the APD group. These re-
sults indicate that APD could effectively treat SAP accom-
panied by serum TG and FFA elevation by ameliorating its
clinical outcomes while avoiding additional infection.
APD could reduce the serum levels of TG and FFA
In our previous report, we found that APD exerts a
beneficial effect on SAP patients by reducing intra-
abdominal pressure (IAP) [3]. Considering that not all
SAP patients present high IAP [19–21] and that multiple
causes are involved in the development of SAP [22], it is
necessary to determine whether and which other factors
could be relieved or eliminated during the APD proced-
ure. Numerous studies have revealed the types of sub-
stances that are elevated in the PAAF of SAP patients
and in the animal model of AP [23], including adipo-
kines [24]; proteases [25, 26]; cytokines, such as interleu-
kin (IL)-1β [27], IL-6 [28] and IL-8 [29]; and lipid
metabolites, such as TG and FFA [5, 7, 30, 31]. In our
present study, we demonstrated that APD could signifi-
cantly decrease the serum levels of cytokines, including
CRP, IL-1β, IL-6 and TNF-α, which is consistent with
previous studies [1]. Notably, we found a drastic de-
crease of lipid metabolites such as TG and FFA after
APD treatment. This is supported by some published
evidence that lipid metabolites such as TG and FFA,
which are enriched in PAAF, seem to play a role in the
pathogenesis of SAP [5, 6, 32]. For example, in a clinical
study, Vijay and his colleagues found an enrichment of
FFA in PAAF. Meanwhile, they found that increased
lipid metabolites, especially UFA, but not IL-1β or IL-8,
could cause multi-system organ failure by inducing
necro-apoptosis in animal models of AP [6, 32]. In
addition, Closa and his colleagues revealed that FFA ex-
tracted from PAAF could affect liver function after gaining
access to portal system and exacerbate systemic inflamma-
tion in pancreatitis by interfering with the endogenous
regulatory mechanism of the inflammatory factors upon
the activation of NF-kB in local macrophages. Taken to-
gether, our data demonstrate that APD treatment could
drastically decrease the serum levels of TG and FFA,
which may play the important role in improving the clin-
ical outcomes of SAP patients with TG elevation [5].
The decreased extent of FFA is correlated with the clinical
improvement of SAP
To date, the relationship between TG/FFA and the patho-
genesis of pancreatitis requires further documentation. In
Fig. 3 Receiver operating characteristic (ROC) curve. The Δ-Total FFA presented a discrimination with area under the receiver operating characteristic
curve of 0.831 (P< 0.001, 95 % CI, 0.745–0.917)
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the present study, univariable and multivariable logistic re-
gression analyses showed that the decreased extent of FFA
in plasma after treatment was an independent protective
factor for the clinical improvement of SAP. Furthermore,
the ROC curve indicated that a △-FFA of more than
0.835 mmol/L correlated with the outcomes after treat-
ment. In particular, treatment with APD leads to greater
decreases in serum FFA (APD group: 1.07 ± 0.21 mmol/L
vs non-APD group 0.48 ± 0.10 mmol/L, P < 0.05), thereby
benefiting the clinical improvement of SAP.
How does APD reduce the levels of TG and FFA in
plasma?
The most important finding of this study is that both TG and
FFA could be significantly reduced by APD. One may ask
how APD reduces the levels of TG and FFA in plasma. A pos-
sible explanation is that APD could decrease the serum levels
of TG and FFA via the drainage of PAAF. In addition, through
the analysis of the FFA profiles, we found that the serum levels
of UFA, which could be generated by fat necrosis [6, 32],
decreased significantly in the APD group compared with the
non-APD group. Based on these results, we propose APD
could reduce the TG and FFA levels in two ways: by eliminat-
ing PAAF directly or by ameliorating the fat degeneration and
thus reducing the reactive products indirectly.
Why does abnormal elevation of FFA emerge in non-HTG-
induced SAP patients?
Another important observation of this study is that the
concentration of total FFA in plasma was greatly ele-
vated and was accompanied by the elevation of TG in
non-HTG-induced SAP patients. Possible explanations
for this result are that (i) the excess amounts of TG in
the circulation are hydrolyzed by high levels of pancre-
atic lipase, thus resulting in the very high concentration
of FFA [8] and (ii) a large amount of FFA is generated
via fat necrosis [32]. However, under any conditions, the
concentration of FFA might inevitably exceed the bind-
ing capacity of plasma albumin and finally self-aggregate
to FFA micelles, which are responsible for pancreatic is-
chemia and vessel necrosis [33].
Conclusion
In conclusion, we found that APD is beneficial for non-
HTG-induced SAP patients with elevated TG and PAAF.
Notably, we revealed a novel mechanism through which
the reduction of serum TG and FFA may account for the
beneficial effect. Our findings provide new insight into the
indications for APD and mechanisms of its effectiveness,
which may advance the clinical efficacy of APD for SAP.
Limitations and future study
Because of its retrospective design, this study has some
limitations. First, it is difficult to avoid a data bias from
the analysis because of derandomization. Second, the
serum levels of TG and FFA vary in cases of pancreatitis
with different etiologies and in different phases of treat-
ment. When selecting cases, we excluded patients with a
history of hyperlipidemia or alcoholism in an effort to
exclude factors other than fat necrosis that might gener-
ate TG and FFA. Moreover, patients who had undergone
routine antihyperlipidemic therapy throughout treat-
ment were also excluded. Nonetheless, nutritional sup-
port during the treatment might have partly influenced
the results. In addition, though we recommended APD
as an optimal intervention for SAP patients with PAAF
in the early stage of disease in current and previous
studies, there is a need for prospective research to fur-
ther determine the indications for APD.
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